Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 10;2(2):252-96.
doi: 10.3390/vaccines2020252.

Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators

Affiliations
Review

Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators

Elke S Bergmann-Leitner et al. Vaccines (Basel). .

Abstract

The mechanism by which vaccine adjuvants enhance immune responses has historically been considered to be the creation of an antigen depot. From here, the antigen is slowly released and provided to immune cells over an extended period of time. This "depot" was formed by associating the antigen with substances able to persist at the injection site, such as aluminum salts or emulsions. The identification of Pathogen-Associated Molecular Patterns (PAMPs) has greatly advanced our understanding of how adjuvants work beyond the simple concept of extended antigen release and has accelerated the development of novel adjuvants. This review focuses on the mode of action of different adjuvant classes in regards to the stimulation of specific immune cell subsets, the biasing of immune responses towards cellular or humoral immune response, the ability to mediate epitope spreading and the induction of persistent immunological memory. A better understanding of how particular adjuvants mediate their biological effects will eventually allow them to be selected for specific vaccines in a targeted and rational manner.

Keywords: Th1; Th17; Th2; adjuvant; immune epitope; immune mechanism; infectious disease; mucosal immunity; vaccine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
This figure provides a highly simplified overview of Pattern Recognition Receptors (PRR) and the molecular events triggered by the recognition of Pathogen Associated Molecular Patterns (PAMPs) on/inside pathogens. Immune cells as well as many somatic cells express soluble extracellular (not shown), cell surface, and intracellular sentinels for detecting infections. These receptors are specific for distinct classes of pathogen (i.e., bacteria, viruses, fungi, parasites) and are strategically positioned: e.g., receptors that recognize surface components of bacteria such as LPS or LTA are present extracellularly or as soluble molecules (e.g., Mannan-Binding Protein, MBP); receptors for viral RNA are located inside the cell (cytoplasm and phagosome). Binding of PRR to their specific PAMP activates a signaling cascade which relies on common adapter molecules (e.g., MyD88, TRIF), and results in the downstream translation of numerous gene products. Adjuvants emulate these interactions between pathogen and immune system.

References

    1. Hilleman M.R. Vaccines in historic evolution and perspective: A narrative of vaccine discoveries. Vaccine. 2000;18:1436–1447. doi: 10.1016/S0264-410X(99)00434-X. - DOI - PubMed
    1. Dormitzer P.R., Tsai T.F., del Giudice G. New technologies for influenza vaccines. Hum. Vaccines Immunother. 2012;8:45–58. doi: 10.4161/hv.8.1.18859. - DOI - PubMed
    1. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature. 1967;216:160–162. doi: 10.1038/216160a0. - DOI - PubMed
    1. Wijayalath W., Cheesman S., Tanabe K., Handunnetti S., Carter R., Pathirana S. Strain-specific protective effect of the immunity induced by live malarial sporozoites under chloroquine cover. PLoS One. 2012;7:e45861. - PMC - PubMed
    1. Schwartz J.L. The first rotavirus vaccine and the politics of acceptable risk. Milbank Q. 2012;90:278–310. doi: 10.1111/j.1468-0009.2012.00664.x. - DOI - PMC - PubMed